Integrum has sold and delivered OPRA[TM] Implant Systems to a value of SEK 3.5 million to Center of Excellence in Ukraine
Mölndal, Sweden – January 31, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company today has sold and delivered OPRA™ Implant Systems to a value of SEK 3.5 million to Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, Ukraine.
Integrum helped establish the Center of Excellence in December 2023, and two senior surgeons have been trained and certified to perform surgeries on both transfemoral and transhumeral amputees using Integrum’s innovative OPRA™ Implant System. Following a successful establishment, the Center of Excellence today completed a major purchase to secure continuous access to the OPRA Implant System.
“There is a great need for amputee care in Ukraine following the brutal Russian invasion. Our innovative implant system that attaches directly to the skeleton is the very best option for many amputees where an ordinary socket prosthesis, for different reasons, is not possible to use. It is satisfying that The Center of Excellence in Kyiv is now fully operational and that more and more amputees can be offered the best possible care,” says Rickard Brånemark, CEO of Integrum.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 31-01-2024 23:32 CET.
For more information, please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.
ABOUT INTEGRUM
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.